MedX Health Corp. (TSX-V: MDX) has applied to the TSX Venture Exchange for a final 30-day extension to May 15, 2026, to complete additional closings of its non-brokered private placement of Series IV Convertible Loan Notes.

The company completed an initial closing on February 27, 2026, raising $2.7 million through the issuance of Series IV Notes. The extension would allow MedX to raise up to an additional $2.3 million through further closings.

The Series IV Notes carry a 6% annual interest rate paid quarterly and mature on December 31, 2028. Note holders may convert their securities into units at $0.10 per unit until maturity. Each unit consists of one common share and half of a share purchase warrant, with each full warrant exercisable at $0.125 until the maturity date.

Holders of Series I Convertible Loan Notes, which matured on December 31, 2025, may exchange their notes for Series IV Notes. The Series I Notes had a conversion price of $0.14 and warrant exercise price of $0.20.

Qualified agents will receive a 6% cash commission on gross proceeds from subscribers they introduce, plus agent's warrants equal to 6% of those subscriptions. The agent's warrants are exercisable at CAD$0.10 for units comprising one common share and half of a share purchase warrant exercisable at CAD$0.125.

The company stated that certain insiders may participate in the placement, subject to regulatory exemptions. Proceeds will fund redemption of unconverted Series I Notes, development of the company's SIAscopy technology and DermSecure telemedicine platform, expansion into occupational health markets, and general corporate purposes.

MedX Health operates a medical technology platform focused on non-invasive skin screening and teledermatology through proprietary imaging technology cleared for use in multiple jurisdictions including Canada, the United States, and the European Union.